The Case Report Presentation Session will take place on Friday, October 6 at the start of the meeting and will feature oral presentations of unique and challenging cases. The case should be either one that is unusual, or a common problem with some unusual or challenging aspect. Submissions will open on June 15 and close on July 24. Notifications for acceptance will be sent in August.
If accepted, the lead author will present the case in the session, with additional discussion lead by HFSA moderators and leadership. The case will not be published in the JCF abstract supplement.
- Only one case study per candidate will be considered.
- The applicant must be the first and presenting author, although the abstract may have co-authors. The presenting author of an accepted abstract must be registered for and attend the HFSA Annual Scientific Meeting.
- The work covered by the case report abstract must not have been presented at a national or international meeting or world congress before the date and time of presentation at the ASM, or previously published.
Cases should be submitted through the Late Breaking Clinical Trial portal, located here:
You will click a box while submitting to indicate it is a Case, not a Late Breaking Trial. The submission will be preliminarily labeled as a trial, but as long as the box is checked and the description is included, it will be graded and selected as a case.
Case report submissions are formatted in the same manner as a general or LBCT abstracts. They will also require an additional brief write-up/description of the case. The case should be either one that is unusual, or a common problem with some unusual or challenging aspect. The submission description should briefly outline the clinical presentation, supporting diagnostic studies, diagnostic possibilities, conclusions, and implications.
If your case report is accepted for the Case Report Presentation and was also submitted for general abstract/poster presentation at the HFSA Annual Scientific Meeting, you will need to notify HFSA to have it withdrawn from the general abstract sessions and supplement.
- If the work covered by the submitted case report abstract was already submitted to or accepted by the general abstract submissions, it will be withdrawn from the general abstracts and not published in the abstract supplement.
- Authors should submit a case abstract in accordance with HFSA rules and regulations for abstract submission word count, formatting, etc. Authors will submit an abstract based on their case presentation.
- Authors should also submit a brief write-up or description of the case. The case should be either one that is unusual, or a common problem with some unusual or challenging aspect. The submission write up should outline the clinical presentation, supporting diagnostic studies (including relevant images, ECG tracings etc.), and discuss the diagnostic possibilities, conclusions and implications.
- Authors will be required to submit disclosures for themselves and all listed co-authors.
- The size limit for an abstract submission is 2800 Characters. This count includes characters in the following: Abstract Title, Abstract Body, Table(s), and Image(s). It does not include the write-up.
- Use generic names wherever possible. Product-based names are to be used only when necessary.
- Avoid beginning sentences with numerals.
- Standard abbreviations may be used without definition. Nonstandard abbreviations (minimum number) should be placed in parentheses after the first use of the word or phrase abbreviated.
- No references, credits or grant support should be included in the abstract.
- No identifying information about patients participating in a study or trial should be used (name or personal information).
- Check category for submission carefully to assure proper scientific consideration.
- Proofread abstracts carefully to avoid errors before submission. No corrections will be allowed once abstract has been submitted.
- A Table/Image removes 320 characters from your character limit.